FS Development Corp. II
Status: Deal Closed
U=S
| IPO Proceeds, $M | $201.25M |
|---|---|
| IPO Date | Feb 17, 2021 |
| CEO | Jim Tananbaum |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology and life science infrastructure |
| IPO Geography | Global |
| Target Company | Pardes Biosciences |
| Deal Announced | Jun 29, 2021 |
| Deal Size, $M | $339.20M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings | www.sec.gov |
| Approval Vote | Dec 23, 2021 |
| Amendment Vote | TBD |
| Closing Date | Dec 23, 2021 |
Formerly FSII
PRDS
| Price | 2.13 |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on FS Development Corp. II:
- Structure and cap table
- 7 directors & officers
- 20 filings and events
- 1 underwriters
- 4 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Jim Tananbaum | 57 | President, Chief Executive Officer and Director |
| Dennis Ryan | 65 | Chief Financial Officer |
| Michael Rome | 36 | Vice President and Director |
| Daniel Dubin | 55 | Director |
| Owen Hughes | 46 | Director |
| Deepa Pakianathan | 56 | Director |
| Alisa Mall | 43 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Jefferies | BR | 17,500,000 | units |
| 17,500,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.